Harout Semerjian
President and Chief Executive Officer, Board of Directors Member
Harout Semerjian has served as President and Chief Executive Officer since August 2025.
Background
Prior to joining Geron, Mr. Semerjian served as Chief Executive Officer of GlycoMimetics, a clinical-stage biotechnology company, from August 2021 to February 2025. Before that, he served briefly as Chief Executive Officer of Immunomedics in 2020 prior to its acquisition by Gilead Sciences. From March 2018 to April 2020, Mr. Semerjian served as Executive Vice President, Chief Commercial Officer at Ipsen Pharma, a global biopharmaceutical company, where he was responsible for global commercial strategy, portfolio planning, and brand leadership across oncology, neuroscience, and rare disease. From February 2017 to February 2018, he served as President of Ipsen’s Specialty Care International Region and Global Franchises, where he led operations across Europe, Asia-Pacific, and Latin America.
Prior to Ipsen, Mr. Semerjian held multiple commercial and general management roles of increasing responsibility at Novartis from 2001 to 2017, most recently serving as Senior Vice President and Global Launch Leader for KISQALI®, where he led cross-functional launch preparations across global markets. Earlier at Novartis, he led the U.S. hematology franchise and commercial efforts for several key oncology brands, including serving as the global brand director for Gleevec®. Since October 2023, Mr. Semerjian has also served as a member of the Board of Directors at the Biotechnology Innovation Organization.
Mr. Semerjian holds a B.S. in Biology from the Lebanese American University in Lebanon and an MBA from Cornell University as well as from Queen’s University in Canada.